SRx Health Solutions, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SRx Health Solutions, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Aug 31, 2018 | $475 | Dec 21, 2018 |
| FY2018 | Aug 31, 2017 | $1.7K | Dec 21, 2018 |
| FY2017 | Aug 31, 2016 | $48 | Nov 29, 2017 |
| FY2016 | Aug 31, 2015 | $0 | Dec 5, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $6.53M | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | $34.98M | Mar 31, 2025 |
| FY2024 | Jun 1, 2024 | $2.00M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $38.59M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $54.66M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $46.01M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $42.59M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $15.58M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $14.79M | May 4, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Aug 31, 2017 | $1.4K | Nov 29, 2017 |
| FY2017 | Aug 31, 2016 | $43 | Nov 29, 2017 |
| FY2016 | Aug 31, 2015 | $0 | Dec 5, 2016 |
| FY2015 | Aug 31, 2014 | $0 | Nov 18, 2015 |
| FY2014 | Aug 31, 2013 | $0 | Dec 4, 2014 |
| FY2013 | Aug 31, 2012 | $0 | Nov 26, 2013 |
| FY2012 | Aug 31, 2011 | $0 | Dec 13, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.53M | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | $12.99M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $11.80M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $15.26M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $15.37M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $16.11M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.86M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $7.30M | May 4, 2020 |
| FY2018 | Aug 31, 2018 | $264 | Dec 21, 2018 |
| FY2018 | Aug 31, 2017 | $1.4K | Dec 21, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($45.01M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | ($168.0K) | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | ($43.05M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | ($22.77M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($39.32M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $3.39M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($59.34M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($184.46M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($6.03M) | May 4, 2020 |
| FY2018 | Aug 31, 2018 | ($2.95M) | Dec 21, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($11.41M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | ($5.97M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($21.18M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($38.78M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($17.28M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($27.32M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($36.33M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($5.16M) | May 4, 2020 |
| FY2018 | Aug 31, 2018 | ($527.9K) | Dec 21, 2018 |
| FY2018 | Aug 31, 2017 | ($524.0K) | Dec 21, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $100.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $100.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $500.0K | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $500.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $100.0K | Mar 29, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $12.93M | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | $18.96M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $24.44M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $35.43M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $28.51M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $34.49M | Mar 29, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($8.14M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | ($4.36M) | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | ($1.48M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | $97.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($20.55M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($11.86M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($7.51M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($20.97M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($6.90M) | May 4, 2020 |
| FY2017 | Aug 31, 2017 | ($39.8K) | Nov 29, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $41.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $18.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $198.0K | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $353.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $151.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $110.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $31.0K | May 4, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.40M | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | $15.80M | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | $33.76M | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | $16.74M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $38.68M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $74.66M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $51.25M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $53.53M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.99M | May 4, 2020 |
| FY2018 | Aug 31, 2018 | $209.1K | Dec 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.00M | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | $7.15M | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | $88.88M | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | $13.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $17.15M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $16.79M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $79.36M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $50.04M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $9.03M | May 4, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $407.0K | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | $8.65M | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | ($55.12M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | $2.98M | Mar 31, 2025 |
| FY2025 | Sep 30, 2023 | ($33.78M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2022 | $21.53M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $57.88M | Apr 12, 2024 |
| FY2022 | Dec 31, 2020 | ($28.10M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($7.07M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | ($3.04M) | Mar 30, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $405.0K | Mar 31, 2025 |
| FY2025 | Sep 30, 2023 | $18.35M | Dec 5, 2025 |
| FY2022 | Dec 31, 2022 | $0 | Mar 28, 2023 |
| FY2023 | Dec 31, 2021 | $18.61M | Apr 12, 2024 |
| FY2022 | Dec 31, 2020 | $18.61M | Mar 28, 2023 |
| FY2020 | Dec 31, 2019 | $18.61M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 4, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($22.93M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | ($321.51M) | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | ($70.03M) | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | ($321.34M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($298.57M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($259.26M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($260.64M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($201.27M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($16.70M) | May 4, 2020 |
| FY2018 | Aug 31, 2018 | ($6.06M) | Dec 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.31M | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | $3.07M | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | $106.0K | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | $4.46M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.17M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $21.73M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.93M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $2.36M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $3.95M | May 4, 2020 |
| FY2018 | Aug 31, 2018 | $199.7K | Dec 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.41M | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | $32.27M | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | $4.62M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.44M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $10.27M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $32.61M | Mar 29, 2022 |
| FY2019 | Dec 31, 2019 | $37.25M | May 4, 2020 |
| FY2019 | Dec 31, 2018 | $6.20M | May 4, 2020 |
| FY2018 | Aug 31, 2018 | $1.03M | Dec 21, 2018 |
| FY2018 | Aug 31, 2017 | $554.0K | Dec 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (2) | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | 0 | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | (1) | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | (32) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (58) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | (7) | Mar 29, 2022 |
| FY2017 | Aug 31, 2017 | 0 | Nov 29, 2017 |
| FY2017 | Aug 31, 2016 | 0 | Nov 29, 2017 |
| FY2016 | Aug 31, 2015 | 0 | Dec 5, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (2) | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | 0 | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | (1) | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | (32) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (58) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | (7) | Mar 29, 2022 |
| FY2017 | Aug 31, 2017 | 0 | Nov 29, 2017 |
| FY2017 | Aug 31, 2016 | 0 | Nov 29, 2017 |
| FY2016 | Aug 31, 2015 | 0 | Dec 5, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 24.92M | Dec 5, 2025 |
| FY2024 | Dec 31, 2024 | 1.83M | Mar 31, 2025 |
| FY2025 | Sep 30, 2024 | 22.50M | Dec 5, 2025 |
| FY2024 | Dec 31, 2023 | 729,026 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 668,869 | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 29.15M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 8.65M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 47.98M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 11.66M | May 4, 2020 |
| FY2018 | Aug 31, 2018 | 79.68M | Dec 21, 2018 |